AmacaThera Announces Phase 1 Results of First-in-Human Study with AMT-143, Exceeding Expectations and Paving the Way for a Novel Approach to Post-Operative Pain Relief

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

AmacaThera-HumanStudy

More Like This

PR Newswire associated0

AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain

(Photo: Business Wire)

ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain

Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001

Figure 1: Mean NPRS Over Time in Phase 3 Study of Acute Pain Following Abdominoplasty (Graphic: Business Wire)

Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting

Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity

Gynica announces First-in-Human Clinical Trial of Novel IntraVag© Treatment for Endometriosis

Pain Cloud® Launch: A Collaboration between EptivA and Infopoly Ltd., creating an advanced solution to Pain Research